Breathe Well Live Well
|
Glaxo starting late-stage study of asthma drug
CBS News British drugmaker GlaxoSmithKline PLC said Monday that it is starting two late-stage patient studies of an experimental biologic drug as an add-on treatment for patients with severe, uncontrolled asthma. Both studies will compare the safety and … |
View full post on asthma – Google News
|
Glaxo starting late-stage study of asthma drug
Businessweek British drugmaker GlaxoSmithKline PLC said Monday that it is starting two late-stage patient studies of an experimental biologic drug as an add-on treatment for patients with severe, uncontrolled asthma. Both studies will compare the safety and … GlaxoSmithKline starts final-stage tests on severe asthma drug GSK Begins Phase lll Program for Mepolizumab in Severe Refractory Asthma GSK starts final-stage tests on severe asthma drug |
View full post on asthma – Google News
|
GlaxoSmithKline starts final-stage tests on severe asthma drug
Fox News Severe refractory asthma only affects around 4 percent of patients with the disease, so the drug may not become a major seller for GSK but could consolidate the group's strong grip on the market for lung drugs. Print; Email; Share; Comments; Recommend … GSK Begins Phase lll Program for Mepolizumab in Severe Refractory Asthma GSK starts final-stage tests on severe asthma drug |
View full post on asthma – Google News
|
GSK starts final-stage tests on severe asthma drug
Reuters Severe refractory asthma only affects around 4 percent of patients with the disease, so the drug may not become a major seller for GSK but could consolidate the group's strong grip on the market for lung drugs. (Reporting by Ben Hirschler). Health … GSK Begins Phase lll Program for Mepolizumab in Severe Refractory Asthma |
View full post on asthma – Google News
|
Research and Markets: Global Asthma Drug Pipeline Capsule – 2012 Update
The Herald | HeraldOnline.com Fore Pharma's latest report "Global Asthma Drug Pipeline Capsule – 2012 Update" provides most up-to-date information on key Research and Development activities (R&D) in the global Asthma market. It covers active Asthma pipeline molecules in various … |
View full post on asthma – Google News
|
Mylan settles suit over asthma, allergy drug
Drug Store News PITTSBURGH — Mylan has settled a patent infringement suit over a drug used to treat respiratory diseases, Mylan said. The generic drug maker said it resolved a patent litigation suit filed by Shionogi and Cima Labs over prednisolone sodium phosphate … |
View full post on asthma – Google News
|
Dr Reddy's launches anti-asthma drug
Hindu Business Line The drug is used for treating asthma and seasonal allergies. The move follows the approval by the United States Food & Drug Administration (USFDA) of Dr Reddy's Abbreviated New Drug Application for Montelukast Sodium Oral Granules, a company press … Dr Reddy's launches generic anti-asthma drug in US market Dr. Reddy's introduces generic Singulair oral granules in the US |
View full post on asthma – Google News
|
Dr Reddy's launches generic anti-asthma drug in US market
Moneycontrol.com … 2012 at 20:36. Dr Reddy's launches generic anti-asthma drug in US market. Drug maker Dr Reddy's Laboratories has launched its generic Montelukast Sodium oral granules used for treating asthma and seasonal allergies in the US market. Source: PTI … |
View full post on asthma – Google News
|
Dr Reddy's Laboratories launches generic anti-asthma drug in US market
Economic Times NEW DELHI: Drug maker Dr Reddy's Laboratories has launched its generic Montelukast Sodium oral granules used for treating asthma and seasonal allergies in the US market. The launch was made on September 26 following approval by the United States … |
View full post on asthma – Google News
|
FDA to rule on Glaxo-Theravance lung drug by May
Businessweek The companies have asked the FDA to approve Breo as a treatment for chronic obstructive pulmonary disease, and they want the European Medicines Agency to approve the drug as a treatment for COPD and asthma. The companies added that on Tuesday … GSK and Theravance Announce FDA Acceptance of FF/VI New Drug Application … GlaxoSmithKline, Theravance say FDA Accepts FF/VI NDA Submission For COPD GSK and Theravance make progress in FDA review of key COPD drug |
View full post on asthma – Google News